昭衍新药:H股公告:致本公司登记股东通知信函及回条

JOINN Laboratories (China) Co., Ltd.
北京昭衍新藥研究中心股份有限公司
(A joint stock company incorporated in the People’s Republic of China with limited liability)
（於中華人民共和國註冊成立的股份有限公司）
（Stock Code 股份代號：6127）
NOTIFICATION LETTER 通知信函
29 April 2025
Dear Registered Shareholders.
JOINN Laboratories (China) Co., Ltd. (the “Company”)
– Notice of publication of 2024 Annual Report (the “Current Corporate Communication”)
The English and Chinese versions of the Company’s Current Corporate Communications are now available on the Company’s website at www.joinnlabs.com and the website of The
Stock Exchange of Hong Kong Limited (the “Stock Exchange”) at www.hkexnews.hk respectively (the “Website Version”). The Company strongly recommends you to access the
Website Version of the Current Corporate Communication and all future Corporate Communications (Note). If you have elected to receive the Corporate Communications in printed
form, the Current Corporate Communication is enclosed.
If you have difficulty in receiving email notification or gaining access to the Website Version of the Corporate Communications and would like to receive the Current Corporate
Communication and all future Corporate Communications in printed form, please complete, sign the enclosed Reply Form and return it to the Company’s H share registrar in Hong
Kong, Tricor Investor Services Limited (“H Share Registrar”) at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by post using the provided prepaid mailing label (no
stamp is needed if posted in Hong Kong) or by email to is-ecom@vistra.com. The Company will promptly upon your request send the Current Corporate Communications to you in
printed form free of charge.
It is the responsibility of registered shareholders to provide a functional email address. If you have not provided your email address to the Company or need to update your
email address, the Company recommends you to provide your email address by completing, signing the enclosed Reply Form and returning to the H Share Registrar at the
above-mentioned address by post or by email to is-ecom@vistra.com. If the Company does not have your functional email address, until such time that the functional email
address is provided to the H Share Registrar, you will be unable to receive via email notices of publication of the Website Version of Corporate Communications (“Notice of
Publication”) and Actionable Corporate Communications in electronic form. As such, the Company would only be able to send you the Notice of Publication and the
Actionable Corporate Communications in printed form.
Should you have any queries relating to this notification, please call the H Share Registrar’s telephone hotline at (852) 2980 1333 from 9:00 a.m. to 6:00 p.m., Monday to Friday
(excluding public holidays).
By the order of the Board
JOINN Laboratories (China) Co., Ltd.
Feng Yuxia
Chairperson
Note: Corporate Communicationsinclude any document(s) issued orto be issued by the Company forthe information oraction of holdersof any of its securitiesor the investing
public, including but not limited to (a) the directors’ report and its annual accounts together with a copy of the auditors’ report and, where applicable, its summary
financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; (f) a proxy form;
and (g) Actionable Corporate Communications.
Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or
make elections as Shareholders.
各位登記股東：
北京昭衍新藥研究中心股份有限公司（「本公司」）
– 2024年度報告（「本次公司通訊」）之登載通知
本公司的本次公司通訊之中、英文版本已分別上載於本公司網站(www.joinnlabs.com)及香港聯合交易所有限公司（「聯交所」）之網站(www.hkexnews.hk) （「網站版本」）。我們建議 閣下閱覽本公司本次及日後公司通訊（附註）的網站版本。如 閣下已選擇收取公司通訊的印刷本，隨函附上本次公司通訊。
如 閣下因任何理由無法以電子郵件方式收取或閱覽公司通訊的網站版本及欲索取本次公司通訊及日後公司通訊的印刷本，請填妥及簽署隨附之回條，並以已預付郵費的郵寄標籤寄回本公司之H股證券登記處（「H股證券登記處」）卓佳證券登記有限公司 （地址為香港夏慤道16號遠東金融中心17樓）（如在香港投寄毋須貼上郵票），或電郵至 is-ecom@vistra.com。本公司會因應 閣下之要求立